SPECIFIC FEATURES OF REFERENCE DRUG PRICING

Download full text PDF
DOI: https://doi.org/None
Issue: 
8
Year: 
2015

Professor V.A. Plotnikov, PhD; S.V. Melnikov Saint Petersburg Chemopharmaceutical Academy; 14, Prof. Popov St., Saint Petersburg 197376

State price regulation that can protect a buyer from the overpayment caused by the initial ignorance of a purchase is one of the main features of the pharmaceutical market due to its social orientation. Reference pricing is one of the main methods for state regulation of prices for medicaments in Europe. Let us consider whether reimbursement systems may be introduced in Russia. The fragile foreign-policy situation and ruble devaluation make additional restrictions to introduce this pricing system. Its creation raises the question about the necessity of making initial reference prices through an external or internal comparison, which highlights the transparency of the data used in the procedures and the choice of compared countries that are most compatible with the level and rates of economic development and foreign policy strategies.
Keywords: 
reference pricing
reimbursement
state price regulation
References: 
  1. Analiticheskiy otchet. Farmacevticheskiy rynok Rossii. Itogi 2013 goda. ZAO «GruppaDSM».[Analytical report. Pharmaceutical market of Russia.The end of 2013. CJSC «DSM Group» (in Russian)].
  2. Brekke K., Grasdal A., Holmås T.H. Regulation and pricing of pharmaceuticals: Reference pricing of price cap regulation? Eur. Econ. Rev., 2009; 53: 170–185.
  3. Dylst P., Vulto A., Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert. Rev. Pharmacoecon Outcomes Res., 2011; 11 (6): 729–737.
  4. Håkonsen H., Horn A.M., Toverud E-L. Price control as a strategy for pharmaceutical cost containment – What has been achieved in Norway in the period 1994–2004? Health Policy, 2009; 90 (2): 277–285.
  5. Dylst P., Vulto A.G. Reference pricing systems in Europe: characteristics and consequences. Generics and Biosimilars Initiative Journal, 2012; 1 (3-4): 127–131.
  6. Portela C. Reference pricing system and competition: case study from Portugal. Croat. Med. J., 2009; 50 (5): 429–439.
  7. Stargardt T., Schreyögg J., Busse R. Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effect. Gesundheitswesen, 2005; 67 (7): 468–477.
  8. Simoens S., De Bruyn K., Bogaert M., Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics, 2005; 23 (8): 755–766.
  9. Kaló Z., Muszbek N., Bodrogi J., Bidló J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy, 2007; 80 (3): 402–412.
  10. Vogler S., Habl C., Leopold C., Rosian-Schikuta I., de Joncheere K. Thomsen T.L. PPRI Report. Vienna, Austria: Commissioned by European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth; 2008.
  11. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries–an overview. Generics and Biosimilars Initiative Journal, 2012; 1 (2) :93–100.
  12. WHO Guideline on Country Pharmaceutical Pricing Policies.World Health Organization. 2013.